Anti-CD9 antibody [EM-04] (ab82390)
Key features and details
- Rat monoclonal [EM-04] to CD9
- Suitable for: WB
- Reacts with: Mouse
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
Anti-CD9 antibody [EM-04]
See all CD9 primary antibodies -
Description
Rat monoclonal [EM-04] to CD9 -
Host species
Rat -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Tissue, cells or virus corresponding to Mouse CD9. Permeabilized murine bone marrow-derived mast cells (BMMC)
-
Positive control
- Lysates from Mouse bone marrow-derived mast cells (BMMC)
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.40
Preservative: 0.097% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
EM-04 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab82390 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 1 µg/ml. Use under non reducing condition. Predicted molecular weight: 25 kDa.
|
Notes |
---|
WB
Use a concentration of 1 µg/ml. Use under non reducing condition. Predicted molecular weight: 25 kDa. |
Target
-
Function
Involved in platelet activation and aggregation. Regulates paranodal junction formation. Involved in cell adhesion, cell motility and tumor metastasis. Required for sperm-egg fusion. -
Tissue specificity
Expressed by a variety of hematopoietic and epithelial cells. -
Sequence similarities
Belongs to the tetraspanin (TM4SF) family. -
Post-translational
modificationsProtein exists in three forms with molecular masses between 22 and 27 kDa, and is known to carry covalently linked fatty acids. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 12527 Mouse
- SwissProt: P40240 Mouse
- Unigene: 210676 Mouse
- Unigene: 404614 Mouse
-
Alternative names
- Tetraspanin 29 antibody
- 5H9 antibody
- 5H9 antigen antibody
see all
Images
-
All lanes : Anti-CD9 antibody [EM-04] (ab82390) at 1 µg/ml
Lane 1 : lysate from 1X10^6 mouse bone marrow-derived mast cell (BMMC)
Lane 2 : lysate from 0.5X10^6 mouse bone marrow-derived mast cell (BMMC)
Lane 3 : lysate from 0.25X10^6 mouse bone marrow-derived mast cell (BMMC)
Lane 4 : lysate from 0.125X10^6 mouse bone marrow-derived mast cell (BMMC)
Performed under non-reducing conditions.
Predicted band size: 25 kDa
Observed band size: 24 kDa why is the actual band size different from the predicted?
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab82390 has been referenced in 4 publications.
- Casadei L et al. In situ hybridization to detect DNA amplification in extracellular vesicles. J Extracell Vesicles 11:e12251 (2022). PubMed: 36043432
- Németh T et al. Lineage-Specific Analysis of Syk Function in Autoantibody-Induced Arthritis. Front Immunol 9:555 (2018). Mouse . PubMed: 29616043
- Murgai M et al. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med 23:1176-1190 (2017). PubMed: 28920957
- Nishida-Aoki N et al. Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis. Mol Ther 25:181-191 (2017). PubMed: 28129113